# Regulatory Digest: DEA Enforcement & Controlled Substances March 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-enforcement-controlled-substances-march-2026/ > **Published:** 2026-03-07T02:38:58-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:10:47-04:00 > **Clinical Summary:** Explore the latest DEA enforcement controlled substances updates and import regulations affecting cannabis and synthetic cannabinoids in March 2026. --- ✦ New ## Regulatory updates (digest-only, lower relevance) - **(57)** [regulations.gov] [Importer of Controlled-Bright Green(2024-20083)DEA1426](https://www.regulations.gov/document/DEA-2024-0111-0001) - **(57)** [regulations.gov] [Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429](https://www.regulations.gov/document/DEA-2024-0110-0001) - **(57)** [regulations.gov] [Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425](https://www.regulations.gov/document/DEA-2024-0112-0001) - **(57)** [regulations.gov] [Importer Controlled-VA Cooperative (2024-11795) DEA1374](https://www.regulations.gov/document/DEA-2024-0064-0001) - **(57)** [regulations.gov] [Importer Controlled- Quagen Pharma (2024-11892) DEA1381](https://www.regulations.gov/document/DEA-2024-0070-0001) - **(47)** [regulations.gov] [Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I](https://www.regulations.gov/document/DEA-2023-0049-0004) - **(45)** [regulations.gov] [Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001) - **(42)** [regulations.gov] [Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0013) - **(42)** [regulations.gov] [Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2024-0118-0001) - **(42)** [regulations.gov] [Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0006) - **(42)** [regulations.gov] [Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0001) - **(42)** [regulations.gov] [Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I](https://www.regulations.gov/document/DEA-2022-0145-0004) - **(38)** [regulations.gov] [Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.regulations.gov/document/DEA-2023-0147-0003) - **(38)** [regulations.gov] [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0007) - **(38)** [regulations.gov] [Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I](https://www.regulations.gov/document/DEA-2023-0168-0001) - **(35)** [regulations.gov] [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0011) - **(35)** [regulations.gov] [Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.](https://www.regulations.gov/document/CMS-2024-0256-0045) - **(35)** [regulations.gov] [Schedules of Controlled Substances: Placement of Metonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0005) - **(32)** [regulations.gov] [Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)](https://www.regulations.gov/document/CMS-2024-0256-0001) - **(5)** [regulations.gov] [Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-F)](https://www.regulations.gov/document/CMS-2023-0121-22025) - **(5)** [regulations.gov] [Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-P)](https://www.regulations.gov/document/CMS-2023-0121-0001) - **(2)** [regulations.gov] [Definition of Engaged in the Business as a Dealer in Firearms](https://www.regulations.gov/document/ATF_FRDOC_0001-0052) Digest-Level Clinical Commentary Dr. Caplan’s Take Clinical Reflection These regulatory notices suggest ongoing DEA scrutiny of cannabis-adjacent import operations and [controlled substance scheduling](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/), which signals that practitioners like myself should remain vigilant about the distinction between federally compliant cannabis products and emerging synthetic cannabinoids that may face accelerated scheduling. The focus on importers and novel compounds indicates the regulatory landscape continues to tighten around unvetted cannabinoid products, reinforcing my practice’s commitment to recommending only well-characterized, state-legal cannabis or pharmaceutically-derived cannabinoids with established safety profiles. While these particular notices don’t directly impact established [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), they underscore the broader trend of federal enforcement against the cannabis supply chain’s peripheral actors, which ultimately affects [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) and product reliability. Clinical Perspective Clinical Perspective These regulatory updates reflect ongoing DEA efforts to manage the evolving landscape of controlled substance importation and scheduling. The items indicate continued regulatory activity around synthetic compounds and controlled precursors, which may have implications for pharmaceutical supply chains and clinical access to certain medications. Clinicians should remain aware of scheduling changes and import restrictions that could affect availability of medications used in clinical practice. Regulatory UpdatesDEA Enforcement[Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/)ImportationScheduling 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Regulatory+Digest+2026-03-07+%40drcaplan&url=) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Regulatory+Digest+2026-03-07+--+via+%40drcaplan.bsky.social+) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - Daily Digest 2026-03-07 - Daily Digest 2026-03-07 - [Regulatory Digest 2026-03-06](https://cedclinic.com/regulatory-digest-2026-03-09/) Further Reading Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Policy Watch: 26 Regulatory Updates — March 08, 2026](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/) Comprehensive review of 26 regulatory updates including DEA scheduling and import controls relevant to cannabis and [controlled substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/). [Read Policy Watch](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/) [Regulatory Digest 2026-03-06](https://cedclinic.com/controlled-substances-rescheduling-2026/) Daily regulatory digest focusing on controlled substances and DEA enforcement actions impacting clinical access and compliance. [Read Digest](https://cedclinic.com/controlled-substances-rescheduling-2026/) [Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) Analysis of 20 recent regulatory updates including DEA import restrictions and scheduling changes affecting cannabinoid products. [Explore Updates](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).